These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 2338366)

  • 21. National adverse drug reaction reporting. 1984-1989.
    Faich GA
    Arch Intern Med; 1991 Aug; 151(8):1645-7. PubMed ID: 1872669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 23. Global harmonization is not all that global: divergent approaches in drug safety.
    Castle GH; Kelly B
    Food Drug Law J; 2008; 63(3):601-22. PubMed ID: 19031662
    [No Abstract]   [Full Text] [Related]  

  • 24. System for voluntary reporting of adverse drug reactions in a university hospital.
    Vorce-West TE; Barstow L; Butcher B
    Am J Hosp Pharm; 1989 Nov; 46(11):2300-3. PubMed ID: 2589347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. International reporting of adverse drug reactions: the WHO program.
    Olsson S
    Semin Dermatol; 1989 Jun; 8(2):72-4. PubMed ID: 2641718
    [No Abstract]   [Full Text] [Related]  

  • 26. National differences in reporting 'pneumonia' and 'pneumonia interstitial': an analysis of the WHO International Drug Monitoring Database on 15 drugs in nine countries for seven pulmonary conditions.
    Koo LC; Clark JA; Quesenberry CP; Higenbottam T; Nyberg F; Wolf MK; Steinberg MH; Forsythe BH
    Pharmacoepidemiol Drug Saf; 2005 Nov; 14(11):775-87. PubMed ID: 15654720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An underrecognized challenge in evaluating postmarketing drug safety.
    Roden DM
    Circulation; 2005 Jan; 111(3):246-8. PubMed ID: 15668350
    [No Abstract]   [Full Text] [Related]  

  • 28. Quality assurance through adverse drug reaction reporting: improving hypnotic prescribing.
    Phillips MS
    Hosp Pharm; 1990 Mar; 25(3):246-8. PubMed ID: 10170509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
    World Health Organization
    World Health Organ Tech Rep Ser; 2005; 929():1-142, backcover. PubMed ID: 16353684
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pharmacovigilance: theoretical and practical aspects].
    Paoletti V; Galeotta G; Mammarella A
    Clin Ter; 1997 Mar; 148(3):67-73. PubMed ID: 9377842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Establishing requirements for the use of terms for reporting adverse drug reactions.
    Venulet J
    Int J Clin Pharmacol Res; 1992; 12(2):61-4. PubMed ID: 1428299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. International monitoring for adverse drug reactions of long latency.
    Fletcher AP; Griffin JP
    Adverse Drug React Toxicol Rev; 1991; 10(4):209-30. PubMed ID: 1793771
    [No Abstract]   [Full Text] [Related]  

  • 33. Standardization of definitions and criteria for causality assessment of adverse drug reactions. Drug-induced blood cytopenias: report of an international consensus meeting.
    Benichou C; Solal Celigny P
    Nouv Rev Fr Hematol (1978); 1991; 33(3):257-62. PubMed ID: 1956763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. WHO Expert Committee on specifications for pharmaceutical preparations.
    World Health Organ Tech Rep Ser; 1996; 863():1-194. PubMed ID: 8952445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Strategy for surveillance of adverse drug events.
    Bright RA
    Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403
    [No Abstract]   [Full Text] [Related]  

  • 36. Form for reporting serious adverse events and product problems with human drug and biological products and devices; availability--FDA. Notice.
    Fed Regist; 1993 Jun; 58(105):31596-614. PubMed ID: 10171452
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improving the quality of adverse drug reaction reporting by 4th-year medical students.
    Rosebraugh CJ; Tsong Y; Zhou F; Chen M; Mackey AC; Flowers C; Toyer D; Flockhart DA; Honig PK
    Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):97-101. PubMed ID: 12642973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The US drug safety system: role of the pharmaceutical industry.
    Gibson BR; Suh R; Tilson H
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):110-4. PubMed ID: 17724741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The management of adverse drug reactions: from diagnosis to signal.
    Edwards IR
    Therapie; 2001; 56(6):727-33. PubMed ID: 11878098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.